NCT01774630View on ClinicalTrials.gov

Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2)

PHASE2CompletedINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

April 10, 2013

Primary Completion Date

December 21, 2020

Study Completion Date

December 21, 2020

Conditions

Leukemia, Myelogenous, Chronic, BCR-ABL Positive

Interventions

DRUG

Nilotinib

300 mg/twice a day

Trial Locations (10)

26953

CH Valence, Valence

31059

CHU de Toulouse, Service d'Hématologie, Toulouse

33076

Institut Bergonié, Bordeaux

33604

Hôpital Haut Lévêque, Service Hématologie, Pessac

35033

Hôpital Pontchaillou, Rennes

49033

CHU Angers, Angers

69495

Centre Hospitalier Lyon Sud, Service Hématologie, Pierre-Bénite

74374

CH d'Annecy, Pringy

78157

Centre Hospitalier de Versailles - Hôpital André Mignot - Service de Médecine B, Le Chesnay

06202

CHU de Nice, Service Hématologie Clinique, Nice

All Listed Sponsors

lead

University Hospital, Bordeaux

OTHER

NCT01774630 - Multicenter Single-arm Pilot Study Evaluating Efficacy of Nilotinib in CML Patients With Molecular Relapse After Glivec Discontinuation Within the Context of the STIM Trials (STIM and STIM2) | Biotech Hunter | Biotech Hunter